2557-49-5
Chemical Structure
Diflorasone
- CAS No.: 2557-49-5
- Formula:C22H28F2O5
- Molecular Weight:410.45
IUPAC Name: (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
InChIKey: WXURHACBFYSXBI-XHIJKXOTSA-N
SMILES: C[C@@]12[C@](C(CO)=O)(O)[C@@H](C)C[C@@]1([H])[C@]3([H])C[C@H](F)C4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O
Biological Activity: Diflorasone is a potent topical anti-inflammatory Corticosteroid. Diflorasone induces vasoconstriction when applied topically. Diflorasone can be used in research related to psoriasis, atopic dermatitis/neurodermatitis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Diflorasone | 99.84% | Diflorasone is a potent topical anti-inflammatory Corticosteroid. Diflorasone induces vasoconstriction when applied topically. Diflorasone can be used in research related to psoriasis, atopic dermatitis/neurodermatitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Diflorasone (Standard) | ≥98% | Diflorasone (Standard) is the analytical standard of Diflorasone (HY-A0158). This product is intended for research and analytical applications. Diflorasone is a potent topical anti-inflammatory Corticosteroid. Diflorasone induces vasoconstriction when applied topically. Diflorasone can be used in research related to psoriasis, atopic dermatitis/neurodermatitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wickrema Sinha AJ, et al. Percutaneous absorption and excretion of tritium-labeled diflorasone diacetate, a new topical corticosteroid in the rat, monkey and man. J Invest Dermatol. 1978 Dec;71(6):372-7. [Content Brief]
- [2]. Bluefarb SM, et al. Diflorasone diacetate: vasoconstrictor activity and clinical efficacy of a new topical corticosteroid. J Int Med Res. 1976;4(6):454-461. [Content Brief]
